This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
During its Annual Conference, HRS 2024, the HeartRhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF).
milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heartrhythms such as atrial fibrillation (AFib).
An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany. Image courtesy: European Society of Cardiology.
milla1cf Tue, 06/11/2024 - 18:09 June 11, 2024 — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy.
tim.hodson Wed, 03/12/2025 - 15:36 Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrial fibrillation (A-Fib). This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients.
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. Early recurrence of atrial tachyarrhythmia (ERAT) is commonly seen following catheter ablation of AF, with reported incidences of up to 61% in the first three months.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablateheart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. Food and Drug Administration last year, and it is available for cardiac ablation for several products in the company's portfolio, including the THERMOCOOL SMARTTOUCH S F catheter.
milla1cf Thu, 05/30/2024 - 10:31 May 30, 2024 — Stereotaxis , a pioneer in surgical robotics for minimally invasive endovascular intervention, announced the successful treatment of the first heartrhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System.
A multicenter study has described and validated a new strategy for guiding ablation procedures in patients with complex tachycardias. Ablation procedures use energy—usually heat or cold—to eliminate small areas of heart tissue that cause pathological cardiac arrhythmias, thereby restoring normal heartrhythm.
The robotic technology represented an entirely novel way to address heartrhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heartrhythm diseases relies on optimizing interoperability. The company has obtained U.S.
milla1cf Tue, 05/21/2024 - 08:00 May 21, 2024 — Stereotaxis , a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has been invited to present at HRS Africa Summit 2024 , scheduled to take place during HeartRhythm Society Scientific Sessions in Boston, Massachusetts.
UC San Diego Health is the first in San Diego to successfully implant the world’s first dual chamber and leadless pacemaker system to help treat people with abnormal heartrhythms. The most common arrhythmia, atrial fibrillation , will affect approximately 12.1
tim.hodson Wed, 03/12/2025 - 15:36 Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrial fibrillation (A-Fib). This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. 1,ii For patients who had received ablation, median procedure and fluoroscopy times were 90.0 Food & Drug Administration ( FDA ).
Atrial fibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.
Pulsed field ablation (PFA) was shown to be effective in treating patients with paroxysmal atrial fibrillation (AFib), with more patients free from atrial arrhythmias (AA) when compared with patients treated with thermal ablation, according to results from a secondary analysis of the ADVENT trial.
milla1cf Wed, 06/19/2024 - 20:57 June 19, 2024 — When electrophysiologist Eugenio Cingolani, MD , isn’t seeing patients, he can usually be found in his laboratory, investigating improved treatments for heartrhythm disorders. This is a complex procedure that destroys the abnormal heart tissue that’s causing the rapid heartbeat.
At this year’s HeartRhythm Society (HRS) conference in Boston in May, innovation, again, was the focus. PFA on Display As you walked into the expo hall, it was hard to miss the large space-age light displays of the Farapulse Pulsed Field Ablation system from Boston Scientific and the PulseSelect PFA system from Medtronic.
David Newton , Clinical Cardiac Electrophysiologist at Memorial Health University Physicians Heart Care and Dr. Andrea Natale , Executive Medical Director at T exas Cardiac Arrhythmia Institute, St. David’s Medical Center.
Atrial fibrillation often shortened to AFib is an irregular and often rapid heartrhythm that can lead to serious health complications. This increases the pressure inside your ear and chest, which reduces some heartarrhythmias. Cardioversion – This procedure uses electrical shocks to restore a normal heartrhythm.
Atrial fibrillation, or AFib, is the most common type of heartrhythm disorder (arrhythmia), affecting over 6 million Americans, and the number is expected to double by 2030. Catheter ablation is a minimally invasive procedure that disables portions of heart tissue that cause irregular heartrhythms. “In
The patient was started on amiodarone, anticoagulation, and metoprolol, and scheduled for atrial flutter ablation. He underwent ablation in the EP Lab. The KEY to determine is therefore — Does the patient have underlying heart disease?
Since it was announced as a Class 1A recommendation in 2015 by the HeartRhythm Society, cardiac remote patient monitoring has become the standard of care for cardiac device patients. Cardiac implantable devices are sophisticated technology that provide both therapy and diagnostics for patients with irregular heartrhythms.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content